LONDON UROLOGY PARTNERS
For a comprehensive elective and emergency urological service in London
 
 
CONTACT DETAILS
To contact Mr Barry Maraj Consultant Urologist
 
 
EDUCATIONAL BACKGROUND
summary of educational background and urological training
 
 
ACADEMIC BACKGROUND AND PUBLICATIONS
 
 
MEMBERSHIPS
Memberships to important medical associations
 
 
'KEY HOLE' SURGERY
Laparoscopic Urological Operations
 
 
BOTOX and BALDDER PROBLEMS
Botox injections for urinary frequency and urgency
 
 
HAVING A CYSTOSCOPY ?
What is cystoscopy
 
 
HAEMATURIA
Blood in your urine
 
 
HAVING A TURP
A guide for patients having a TURP
 
 
Photosensitive Vaporisation of the Prostate (Green Light)
A revolutionary new day surgery treatment for benign prostate enlargement
 
 
PSA
Prostate Specific Antigen and Prostate Cancer
 
 
Trans-rectal ultrasound (TRUS) guided biopsy of the prostate
Having a TRUS biopsy of your prostate?
 
 
MULTIDICIPLINARY TEAM MEMBERS
GYNAECOLOGISTS, GENERAL SURGEONS, GASTROENTEROLOGISTS, RELAXATION SPECIALISTS AND NUTRITIONISTS
 
 
NEED TO SEE A GP ?
Same day and Emergency call out GP service
 
 
ROBOTIC UROLOGICAL SURGERY
The Da Vinci si system is now widely used for a number of urologic disorders including prostate kidney nad bladder cancer and obstructed kidneys (UPJO)
 
 

ACADEMIC BACKGROUND AND PUBLICATIONS

RESEARCH POST

University of Leeds
Yorkshire Cancer Research Campaign Clinical Research Training Fellow and Honorary Registrar Urology. Molecular Medicine Unit and Department of Urology.
St.James’s University Hospital, Leeds LS9 7TF
Feb1995-Jan1998

This was a three year clinical research training fellowship leading to the degree of PhD. Financial support was kindly provided by the Yorkshire Cancer Research Campaign. The title of my thesis is "Molecular genetic studies of Prostate-specific membrane antigen (PSM)". This was an interesting project in that, unlike PSA which is a secreted glycoprotein, PSM is a surface antigen thought to be selectively expressed by prostate cancer cells. Consequently, PSM has found its potential clinical application in the immunotargeting of prostate cancer patients.

PUBLICATIONS


(1) Intra-arterial temazepam. Scott RN, Going J, Woodburn KR, Gilmour DG, Leiberman DP, Maraj B and Pollock JG. BMJ, 304, 1630 (1992).

(2) Prostate specific membrane antigen: evidence for the existence of a second related human gene. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, Maclennan KA, Meredith DM and Markham AF. British Journal of Cancer, 72, 583-588 (1995).

(3) Prostate-specific membrane antigen genes lie within duplicated regions on human chromosome 11p11.2 and 11q14 loci. Maraj BH, Karayi M, Ali M, Lench NJ, Whelan P and Markham AF. Brithish Journal of Urology, 79 Supp 4, 24-27 (1997)

(4) Detailed characterisation of one human prostate-specific membrane antigen locus on human chromosome 11p11.2. Maraj BH, Ali M, Karayi M, Lench NJ, Whelan P and Markham AF. British Journal of Urology, 80 (1), 170 (1997)

(5) Genetic duplication in the 11p11.2 prostate-specific membrane antigen (PSM) gene-containing region does not extend to the nearby KAI-1 gene locus. British Journal of Urology, 81 Supp 4, 54-55 (1998)

(6) Prostate-specific membrane antigen (PSM): A review. Maraj BH, Whelan P and
Markham AF. British Journal of Urology, 81, 523-528 (1998).

(7) Detailed Genetic Mapping Around A Putative Prostate-Specific Membrane Antigen Locus On Human Chromosome 11p11.2. Maraj BH, Leek J, Karayi M, Ali M and Markham AF. Cytogenetics and Cell Genetics, 81, 3-9 (1998).

(8) Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and prostate cancer immunotherapy. Maraj BH, Alldersley MA and
Markham AF. Lancet, 351, 1559-1560 (1998).

(9) Prostate-specific membrane antigen (FOLH1): Recent advances in characterising this putative prostate cancer gene. Maraj BH and Markham AF. Prostate cancer and prostatic diseases, 2, 180-185 (1999).

(10) Identification of a novel microsatellite marker tightly linked to the KAI-1 gene for predicting prostate cancer progression. Maraj BH, Leek J, Carr IM and Markham AF. European Urology, 37, 228-233 (2000).

(11) Entero-cutaneous fistula of the anterior abdominal wall secondary to LHRH agonist injection. BH Maraj, HS Rogers and J Bellringer. British Journal of Urology, 85, 776 (2000).

(12) Adult Testicular cancer. Maraj, BH and Minhas, S. (2003). Postgarduate diploma in Urology; Rila publications.

(13) Al-Buheissi S, Ghei M, Taylor JS, Markham A, Maraj BH
A novel highly specific polyclonal anti-prostate specific membrane antigen (PSMA) antibody. Urological Association Annual Meeting Sep 2004 Germany

(14) Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ, Shah J, Malone-Lee J.
Effects of Botulinum Toxin B on Refractory Detrusor Overactivity: A Randomised, Double- Blind, Placebo Controlled, Cross Over Trial.
J Urol. 2005 Nov; 174 (5):1873-1877

(15) Ghei M, Nathan S, Maraj BH, Malone-Lee J G and Miller R
Autonomic side effects of Botulinum toxin Type B Intravesical injections: Report of 4 cases and review of the literature
Int Urol Nephrol. 2006;38(3-4):543-4.

(16) Ghei M, Nathan S, Maraj BH, Malone-Lee J G and Miller R.
A day case technique for administration of intradetrusor Botulinum toxin B under sedo-analgesia in neuropathic and non-neuropathic detrusor overactivity: Endoscopic Neurostabilisation (ENS).
Int Urol Nephrol issue 4, 2005

(17) Ghei M, Arun B, Nathan S, Miller R, Maraj BH
Finger guided transrectal biopsy of the prostate: A modified and safe technique.
Ann R Coll Surg Engl 2005 Sep 86(5): 386-387

(18) Ghei M, Arun B, Maraj BH, Miller RA, Nathan S.
Angioleiomyoma of the spermatic cord: A rare scrotal mass.
Int Urol Nephrol 2004 (accepted for publication, issue 4, 2005)

(19) Ghei M, Arun B, Khan A, Maraj BH, Nathan S, Malone-Lee J G and Miller R.
A day case technique for administration of intradetrusor Botulinum toxin B under sedo-analgesia in neuropathic and non-neuropathic detrusor overactivity: Endoscopic Neurostabilisation (ENS).
Journal of Endourology (August 2005)

(20) Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ, Shah J, Malone-Lee J.
Effects of Botulinum Toxin B on Refractory Detrusor Overactivity
Neurourology and Urodynamics (August 2005)



(21) Ghei M, Maraj BH, Miller R, Nathan S, Malone-Lee J.
Effects of Botulinum Toxin B on Refractory Detrusor Overactivity: A Randomised, Double- Blind, Placebo Controlled, Cross over Trial
BJU Intl (June 2005)

(22) Al-Buheissi S, Ghei M, Taylor JS, Markham A, Maraj BH
Immunochemical characterisation of PSMA antibody
Eur Urology (Apr 2005)

(23) Ghei M, Maraj BH, Miller R, Nathan S, Malone-Lee J
Botulinum toxin B: Another effective peptide for the overactive bladder.
ICS UK 2005 Glasgow

(24) Hunter-Campbell, Maraj B, Mayer A, Huhalov A, Hogarth CJ, Chester K. Biomarker discovery in prostate cancer using surface enhanced laser desorption ionisation ‘time-of-flight’ mass spectrometry. BJUI Vol 97 (3), June 2006, pp 97

(25) Dukic,I, Hussain, M, Al-Buhessi, S, Maraj, BH. An Audit of the quality of urological intra-operative notes. BJUI VOl 99 (4), June 2007, p3

(26) Lunawat, R, Ishii, H, Maraj, BH, Malone-Lee, JG. Evidence against the validity of nitrite testing for urinary tract infection. BJUI VOl 99(4), June 2007, pp 50-51



EDITORIAL COMMENTS and NEWS REPORTS


Michael chancellor MD (Editor, J Urol)
Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ, Shah J, Malone-Lee J.
Effects of Botulinum Toxin B on Refractory Detrusor Overactivity: A Randomised, Double- Blind, Placebo Controlled, Cross Over Trial. Editorial comment.
J Urol. 2005 Nov; 174 (5):1873-1877

Michael chancellor MD (Editor, J Urol)
Urgency, botulinum toxin and how botulinum toxin can help urgency.
J Urol 2005 Sep;174(3):818.
Patricia M. Fernberg (Editor, Urology Times, Cleveland, Ohio USA, September issue)
Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ, Shah J, Malone-Lee J.
Effects of Botulinum Toxin B on Refractory Detrusor Overactivity
ICS Montreal Aug-Sep 2005





CLINICAL PROTOCOLS/TRIALS

(1) The efficacy and safety of botulinum toxin B for the treatment of the overactive bladder in a randomized, double-blind, placebo controlled crossover trial.

(2) " A study of the pathophysiological significance of sterile pyuria in Overactive Bladder and a quest for Human Urothelial Biopods"




Text-only version of this page  |  Edit this page  |  Manage website  |  Website design: 2-minute-website.com